Kornimate/medical-research-clean huggingface dataset:
genomic landscape of egfr mutant nsclc prior to erlotinib and at the time of disease progression

Conditions: Carcinoma, Non-Small-Cell-Lung; Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer

Summary: the investigators propose to conduct a pilot feasibility study of single agent erlotinib in patients with metastatic egfr mutant adenocarcinoma of the lung with up to one prior treatment with the sole purpose of characterizing the genomic landscape before erlotinib and at the time of disease progression. the logistics of obtaining adequate quality fresh tissue specimens for sequencing studies before therapy and at the time of disease progression in patients with advanced lung cancer are complex and a thorough understanding of the practical challenges in conducting a study like this is crucial. the current proposal will include exome and transcriptome sequencing from blood collected at baseline along with tumor samples obtained prior to starting erlotinib and at the time of disease progression (a total of two tissue samples and one blood sample per patient). if carried out successfully, the proposed strategy very likely will lead to a larger and adequately powered study to understand fully evolving molecular changes due to clonal selection under treatment pressure. the pace of progress in the field of sequencing technology currently underway is only likely to accelerate in the near future yielding richer and highly content-rich information. moreover, it is likely that genomic information from dna sequencing and transcriptome will be supplemented by analyses of translatomes and proteomes. the investigators plan to sequence paired tumor specimens from 20 patients with egfr mutant adenocarcinoma of the lung before treatment with erlotinib and at the time of disease progression following treatment with erlotinib. as the investigators expect some drop off (due to unexpected clinical events precluding a second biopsy at the time of disease progression, poor specimen quality and early discontinuation of therapy for non-progression), the investigators will enroll 40 patients in this trial to get 20-paired specimens.


Eligibility criteria:
patient selection * diagnosis of metastatic stage iiib/iv lung adenocarcinoma * presence of known sensitizing mutations in egfr tk domain * consented to hrpo# 201305031 ("tissue and blood acquisition for genomic analysis and collection of health information from patients with thoracic malignancies, suspected -thoracic malignancies, or mesothelioma") * treatment with standard of care erlotinib * at least 18 years of age
biomarkers in parkinsonian syndromes

Conditions: Parkinson Disease; Progressive Supranuclear Palsy; Multiple System Atrophy; Atypical Parkinsonism; Parkinsonism

Summary: this is a prospective observational study to identify biomarkers in parkinson syndromes. patients with parkinsonian syndromes at the early stages of disease will be recruited and will be followed up until their established clinical diagnosis or for at least 5 years. in this population, imaging and wet biomarkers as well as clinical data will b systematically collected.


Eligibility criteria:
iιnclusion criteria: * written informed consent, including consent to monitoring * patients with parkinsonism and disease duration \< 2 years * patients with parkinsonism and disease duration \> 2 years * healthy individuals without any neurological disease exclusion criteria: * drug-induced parkinsonism (eg, neuroleptics, lithium, valproic acid, metoclopramide). * metabolic conditions related parkinsonism (eg, wilson's disease, hypoparathyroidism). * structural lesions on brain magnetic resonance imaging (mri) that explain the symptoms, such as normal pressure hydrocephalus, moderate to severe chronic vascular encephalopathy, cerebral infarction, neoplasm * other serious diseases that indicate a life expectancy of \<5 years. * active participation in other interventional clinical studies

Keywords: parkinson's disease progressive supranuclear palsy multiple system atrophy atypical parkinsonism parkinsonism biomarkers
heart failure food intervention trial: impact of a guideline-based nutrition digital tool in heart failure patient clinical outcomes

Conditions: Heart Failure

Summary: measuring the impact of a guideline-based nutrition digital tool in heart failure patients

the goal of this research clinical trial is to learn understand or learn whether a guideline-based nutrition application (app) called medchefs can help heart failure patients adopt and sustain an evidence-based dietary patterns.

Eligibility criteria:
inclusion criteria: * 18-89 years old at time of enrollment * any type of heart failure diagnosis (e.g., i50.x) between 1/1/2023-present * recent hospital admission (within a year) * race/ethnicity: all race/ethnic groups * location: patients have been treated in the greater east bay division and greater silicon valley division areas. * patients with have at least 1 office/outpatient visit with a primary care physician or cardiologist visit before index date exclusion criteria: * • patients with certain patient history (cognitive disabilities) and end stage renal or metastatic cancer diagnosis * patients with active drug/substance use. patients with heart failure who have active substance use are excluded from the study. hf patients with substance use require additional monitoring and follow up due to potential severe withdrawal symptoms, acute hf exacerbation and drug overdose or medication errors. standard protocol includes additional monitor vital signs (e.g., blood pressure, heart rate) and hf symptoms (e.g., edema, dyspnea), and performing regular laboratory tests (e.g., renal function, electrolytes) which is beyond the clinical and logistical capabilities of this study.

Keywords: heart failure nutrition app evidence-based nutrition recommendations guideline-based nutrition app app-based dietary intervention
a novel vertical y-shaped tunnel approach versus modified coronally advanced tunnel technique, for the treatment of miller class i gingival recession

Conditions: Gingival Recession

Summary: recent plastic procedures have provided satisfactory results in the treatment of gingival recession but there is, presently, a greater need for procedure that cause less surgical morbidity as also provide improved results. in this study we propose a novel vertical tunnel technique as a minimally invasive approach (vertical y-shaped tunnel approach) and evaluate clinical results in comparison to camt, both using ctg. the novel technique allows stability of the graft, maximum coronal vascularity and minimum soft tissue reflection.

the tunnel technique is an approach that optimizes esthetics and predictability because of its ability to avoid releasing critical papillae and maintaining a high level of vascularity at the surgical site to support the grafts. the tunnel technique has a minimally invasive nature since the interdental papillae are left intact and vertical incisions are not performed which results in better esthetics. this technique entailed the placement of a connective tissue graft in the tunnel. complete graft coverage is not mandatory as long as the graft dimensions are sufficient to ensure its survival. avoiding detachment of the highly fragile interdental soft tissue can minimize the risk of losing papilla height in critical esthetic areas, avoid scar formation, maximize the papillary and lateral blood supply to the underlying graft and better stabilize the graft for optimal wound healing recent plastic procedures have provided satisfactory results in the treatment of gingival recession but there is, presently, a greater need for procedure that cause less surgical morbidity as also provide improved results. in this study we propose a novel vertical tunnel technique as a minimally invasive approach (vertical y-shaped tunnel approach) and evaluate clinical results in comparison to camt, both using ctg. the novel technique allows stability of the graft, maximum coronal vascularity and minimum soft tissue reflection.

Eligibility criteria:
inclusion criteria: 1. age above 18 years old. 2. the presence of miller's class i gingival recession (25). 3. recession defect on maxillary incisors, maxillary and mandibular canines, or premolars. 4. absence of a history of periodontal surgery at the involved sites in the last 12 months. 5. history of compliance with oral hygiene instructions and periodontal recall. 6. sufficient palatal donor tissue thickness (\> 2mm). 7. clearly identifiable cemento-enamel-junction (cej) exclusion criteria: 1. patients with systemic illness known to affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc (26). 2. pregnant and lactating women 3. current use of any form of tobacco.

Keywords: gingival recession modified tunnel technique tunnel technique connective tissue graft minimally invasive root coverage
randomized multicentre study comparing tep with lichtenstein repair for primary inguinal hernia

Conditions: Inguinal Hernia

Summary: the purpose of this study was to compare the recurrence rate after tep (laparoscopic method) and lichtenstein (open method) repair on primary inguinal hernia.


Eligibility criteria:
inclusion criteria: * male * age 30-70 years referred to hospital with a primary inguinal hernia. exclusion criteria: * recurrent hernia * scrotal or bilateral hernia * previous lower abdominal surgery * unable to participate in follow up * asa more than 3 * bleeding diathesis.

Keywords: recurrence rate after inguinal hernia repair on primary inguinal herina.
using clinicopathomic markers to predict neoadjuvant chemotherapy response in breast cancer

Conditions: Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma

Summary: this study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. the hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pcr) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.

the specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of metastasis from primary breast cancer to other distant sites, (3) determine the rates of local recurrence in breast cancer patients, and (4) to determine if there are significant radiomic, pathomic, and clinical markers for recurrence and distant metastasis.

Eligibility criteria:
inclusion criteria: * participants must be men and women age 18+ * biopsy-confirmed diagnosis of invasive breast cancer; (er+/-, pr+/-, her2+/-) * any state of disease as described by ajcc v7 criteria * participants must have received and completed neoadjuvant chemotherapy exclusion criteria: * participants who had other primary cancers prior to breast cancer

Keywords: radiomics pathomics breast cancer machine learning biomarkers
study of s-588410 after adjuvant chemotherapy for completely resected non-small- cell lung cancer

Conditions: Non-small- Cell Lung Cancer

Summary: in this clinical study, the investigators evaluate the efficacy and safety of s-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

in this phase ii trial, the investigators evaluate the efficacy and safety of s-588410 containing oncoantigens-derived hla-a\*2402-restricted epitope peptides in patients with hla-a\*2402 who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Eligibility criteria:
inclusion criteria: 1. patients who received platinum-based adjuvant chemotherapy after the complete resection of lung cancer. 2. pathologically determined non-small-cell lung cancer excepting the large cell neuroendocrine carcinoma and mixed type. 3. patients with hla-a\*24:02. 4. neither recurrence nor metastasis of non-small-cell lung cancer demonstrated by imaging tests within 6 weeks prior to the registration. 5. possible to receive s-588410 within 12 weeks after the last adjuvant chemotherapy. 6. ecog performance status 0 or 1 within 2 weeks prior to the registration. 7. age over 20 years at time of consent acquisition. 8. the written informed consent provided by the patient. exclusion criteria: 1. other malignant diseases requiring treatment, excepting the cured cancer in-situ. 2. concurrent treatment with anticancer drug, steroids, immunosuppressive agent, radiotherapy, immunotherapy, hyperthermia, or surgery. 3. active and uncontrolled infectious disease. 4. severe hepatic dysfunction, kidney dysfunction, cardiac disease, pulmonary disease, hematological disorder, or metabolic disease. 5. coronary artery stenting within 6 months prior to registration. 6. autoimmune disease. 7. hiv infection. 8. registration within 4 weeks after the last adjuvant chemotherapy. 9. laboratory values defined in the protocol within 2 weeks prior to registration. 10. residual uncontrolled adverse events by adjuvant chemotherapy. 11. eosinophilia within 28 days prior to registration. past or active eosinophilic pneumonia or interstitial pneumonitis. 12. past history of severe allergic reaction against drug, vaccine and biological agents. 13. female patient in nursing or pregnancy. 14. refusal of pregnancy conception. 15. treated with the same peptide vaccines as s-588410. 16. treated with another investigational drug within 28 days prior to registration or the period of 5 times of the drug half-life. 17. decision of non-enrollment of the patients by principal investigator or physician-in-charge from the view point of patient's safety.
anesthetic efficacy of x-tip intraosseous injection

Conditions: Anesthesia

Summary: * hypothesis: * x-tip intraosseous is an effective supplementary injection in mandibular hot teeth as well as periodontal ligament (pdl) injection * purposes: * comparing the anesthetic efficacy of x-tip intraosseous and pdl injection in mandibular hot teeth which had not been anesthetized after 3.6 ml infra alveolar nerve block * methods and materials: * forty patients with mandibular hot molar or second premolar which had not been anesthetized after 3.6 ml inferior alveolar nerve block injection will be selected for this study

* randomization: * all patients will be randomly divided into two groups as follows: 1. x-tip intraosseous injection will be used as supplementary 2. pdl injection will be used as supplementary * anesthetic evaluation: * for anesthetic evaluation we will use visual analog scale (vas)

Eligibility criteria:
inclusion criteria: * mandibular molars and second premolars with acute irreversible pulpitis * none of the teeth selected should have been anesthetized following 3.6 ml lidocaine block injection exclusion criteria: * unhealthy patients * teeth which were anesthetized following 3.6 ml nerve block injection * patients who did not have any signs of lip anesthesia following 3.6 ml injection

Keywords: intraosseous injection x-tip pdl injection supplementary injection
safety and efficacy study of de-110 ophthalmic suspension for the treatment of dry eye disease

Conditions: Dry Eye

Summary: investigate the safety and efficacy of two concentrations of de-110 compared to placebo for the treatment of dry eye disease


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of dry eye * not wear contact lenses during study * 18 years or older * understand and provide written consent * negative pregnancy test and use acceptable method of contraception exclusion criteria: * use of any topical ocular medication * any type of ocular surgery * diagnosis of on-going ocular infection and/or allergic conjunctivitis * uncontrolled systemic conditions/lid abnormalities * corneal transplants * females who are pregnant, nursing or planning a pregnancy * participation in another drug trial concurrently or within 30 days prior to study
response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in pediatric patients (study p04299)

Conditions: Rhinitis

Summary: evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in indonesian pediatric patients.

children, ages 2-11, with a history of perennial allergic rhinitis

Eligibility criteria:
inclusion criteria: * children patients of both sexes aged between 2-11 years, of either gender and any race * unequivocal history of perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation * minimum score for inclusion: 10 * capable of complying with the dosing regimen * free of any clinically significant disease (other than allergic rhinitis) * antihistamine must be justified by investigating doctor exclusion criteria: * patients with asthma who require chronic use of inhaled or systemic corticosteroids * history of frequent, clinically significant sinusitis or chronic purulent postnasal drip * patients with rhinitis medicamentosa * history of hypersensitivity to desloratadine or any of its excipients * doctor deems unsuitable
role of nlrp6 in chronic periodontitis

Conditions: Chronic Periodontitis

Summary: the quantification of nlrp6 in blood samples will be analyzed from individuals with chronic periodontitis but without systemic disease. demographic and periodontal parameters will be assessed and correlated with the nlrp6 quantification using rt-pcr.

this study aims to collect demographic variables, including age, education level, bmi, personal habits, medication use, and history of systemic disease, from non-smoking individuals with chronic periodontitis. initially, we will determine the expression level of the nlrp6 gene in blood samples taken from chronic periodontitis subjects who are matched for age and sex. subsequently, we will investigate the relationship between gene expression levels, taking into account the confounding effect of body mass index, and explore how these levels correlate with the severity of the disease. in this study, two groups: chronic periodontitis (cp) and healthy controls (hc) will be examined. the cp group will consist of patients diagnosed with stage i to iv periodontitis based on the consensus report from the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. additionally, we will include systemically healthy individuals. serum samples will be collected from all patients, and the plaque index (pi) and gingival index (gi) will be recorded at four sites per tooth. furthermore, we will assess full-mouth probing depth (pd) and clinical attachment level (cal) at six sites per tooth. the percentage of bleeding areas will be documented as the proportion of sites with bleeding on probing (bop) within 20 seconds after probing. for blood sampling, a total of 3 ml of blood will be collected from the antecubital vein of each individual by an expert nurse from the department of periodontology. statistical analysis will be conducted using statistical software for data science (stata version 17). a significance value (p-value) of less than 0.05 will be considered statistically significant. the sample size for the study was determined using the power paired means module in stata 17. we planned to include at least 25 individuals in each group, aiming for a significance level of 5%, statistical power of 80%, and a correlation coefficient of 0.2.

Eligibility criteria:
inclusion criteria: * age: at least 25 years old * clinical diagnosis of chronic periodontitis * at least 15 teeth in the mouth exclusion criteria: * premalignant lesions and cancer of the oral cavity * periodontal treatment in the last 6 months * systemic disorders affecting the periodontal condition (autoimmunity and endocrine disorders) * diabetes mellitus and rheumatoid arthritis * pregnancy or breastfeeding * taking drugs with the possibility of affecting the periodontal condition (calcium channel blockers, anticonvulsants, etc.) * smoking * aggressive pd

Keywords: nlrp6 protein, human chronic periodontitis
nutritious eating with soul at rare variety cafe

Conditions: Obesity

Summary: to date, few dissemination and implementation (d\&i) studies exist of successful healthy eating interventions delivered through restaurant settings. therefore, the proposed study will investigate the following aims: aim 1: examine reach and adoption of a modified, 12-week new soul vegan intervention delivered through a train-the-trainer approach in a soul food vegan restaurant. aim 2: assess resource use and cost associated with a train-the-trainer d\&i approach in a restaurant setting. aim 3: examine effectiveness through changes in participants' diet, self-efficacy, weight loss, and quality of life from baseline to follow-up (3-months) and at maintenance (9-months). aim 4: assess implementation fidelity and participant satisfaction of modified new soul.


Eligibility criteria:
inclusion criteria: * self-identify as african american * between 18-65 years old * be free on meeting night (tuesday at 6pm) * be free of eating disorder * be free of major health or psychiatric diseases, drug or alcohol dependency, thyroid conditions, diabetes, or pregnancy * willing to travel weekly to rare variety café exclusion criteria: * currently following a plant-based/vegan diet * have a body mass index of under 25 or over 49.9 kg/m2 * currently on medication for diabetes * women who are currently pregnant or breastfeeding (or plan to become pregnant in the next 24 months) * currently participating in a weight loss program or taking weight loss medications * recent weight loss (\>10lbs in the last 6 months) * living in the same household as somebody already participating in the larger new soul study at the university of south carolina * currently in the new soul study
effect of virtual reality on perioperative anxiety, stress and pain in total hip arthroplasty

Conditions: Virtual Reality; Total Hip Arthroplasty; Anxiety; Stress; Pain

Summary: the aim of this study is to evaluate virtual reality (vr) on perioperative anxiety, pain, hemodynamics, and stress hormones in patients undergoing total hip arthroplasty (tha).

vr is a computer technology that provides the feeling of being immersed in a simulated three-dimensional (3d) world where the user may interact with the virtual environment. clinical studies have shown that vr technology is effective in reducing pain perception and anxiety. it has also been proposed as an effective non-pharmacological alternative for reducing acute procedural pain and providing anxiety relief.

Eligibility criteria:
inclusion criteria: * age 21 years or above. * both sexes. * the american society of anesthesiologists (asa) physical status i-iii. * scheduled for elective tha under spinal anesthesia. exclusion criteria: * cerebrovascular disease. * psychiatric-cognitive dysfunction. * claustrophobia. * deaf and blind patients. * uncooperative. * adrenal insufficiency. * chronic alcohol and substance addiction. * chronic sedative and narcotic use.